FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
FATE THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.86+0.07 (+3.91%)
Close on Oct 19, 2026
- Market cap
- $223.94M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
59.9%
72M of 120M shares
Institutional holders
155
31 new, 30 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
0 buys · 6 sales
Net sold $322.86K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Goldman Sachs & Co. LLC | 8,487,220 | 7.40% | 13G (passive) | Mar 31, 2025 |
| Boxer Asser Management Inc. | 6,171,000 | 6.30% | 13G (passive) | Jan 31, 2024 |
| Redmile Group, LLC | 18,229,078 | 14.90% | 13D (active) amendment | Apr 20, 2026 |
| Jeremy C. Green | 17,941,579 | 14.90% | 13D (active) amendment | Jul 2, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FATE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Redmile Group, LLC | 12,872,946 | 10.74% | $34.76M | – | 2.33% |
| BlackRock, Inc. | 7,298,895 | 6.09% | $19.71M | −2,769,719 | 0.00% |
| Vanguard Portfolio Management LLC | 4,545,893 | 3.79% | $12.27M | +411,308 | 0.00% |
| Vanguard Capital Management LLC | 4,445,536 | 3.71% | $12.00M | +253,473 | 0.00% |
| Acadian Asset Management LLC | 4,351,250 | 3.63% | $11.74K | +231,050 | 0.01% |
| Aqr Capital Management LLC | 3,837,229 | 3.20% | $10.36M | +835,708 | 0.00% |
| Two Sigma Investments, LP | 3,589,863 | 3.00% | $9.69M | +123,077 | 0.01% |
| Johnson & Johnson | 3,379,064 | 2.82% | $9.12M | – | 1.14% |
| Renaissance Technologies LLC | 2,983,268 | 2.49% | $8.05M | +8,585 | 0.01% |
| Millennium Management LLC | 2,433,978 | 2.03% | $6.57M | New | 0.00% |
| Goldman Sachs Group Inc | 2,049,187 | 1.71% | $5.53M | +721,430 | 0.00% |
| Geode Capital Management, LLC | 1,322,013 | 1.10% | $3.57M | −1,268,416 | 0.00% |
| T. Rowe Price Investment Management, Inc. | 1,080,320 | 0.90% | $2.92K | New | 0.00% |
| Jane Street Group, LLC | 1,027,007 | 0.86% | $2.77M | +380,028 | 0.00% |
| Citadel Advisors LLC | 993,308 | 0.83% | $2.68M | +50,382 | 0.00% |
| Bruce & Co., Inc. | 989,188 | 0.83% | $2.67M | +200,000 | 0.72% |
| Morgan Stanley | 694,580 | 0.58% | $1.88M | −73,168 | 0.00% |
| Vanguard Fiduciary Trust Co | 640,428 | 0.53% | $1.73M | −13,333 | 0.00% |
| Charles Schwab Investment Management Inc | 610,949 | 0.51% | $1.65M | −145,324 | 0.00% |
| UBS Group AG | 590,178 | 0.49% | $1.59M | −1,231,537 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 155 | 72M | 59.9% | 31 / 59 | 35 / 30 | 12M | 14M |
| Q1 2026 | 158 | 74M | 61.8% | 28 / 55 | 34 / 15 | 19M | 8M |
| Q4 2025 | 146 | 72M | 60.3% | 21 / 32 | 53 / 17 | 7M | 15M |
| Q3 2025 | 143 | 81M | 67.3% | 23 / 44 | 38 / 17 | 15M | 14M |
| Q2 2025 | 139 | 80M | 66.6% | 28 / 44 | 41 / 21 | 4M | 21M |
| Q1 2025 | 132 | 97M | 80.6% | 18 / 40 | 40 / 42 | 17M | 21M |
| Q4 2024 | 159 | 102M | 84.9% | 35 / 45 | 47 / 40 | 13M | 28M |
| Q3 2024 | 164 | 117M | 97.3% | 21 / 42 | 59 / 36 | 17M | 14M |
| Q2 2024 | 182 | 124M | 100.0% | 38 / 56 | 50 / 22 | 17M | 24M |
| Q1 2024 | 167 | 131M | 100.0% | 41 / 48 | 52 / 31 | 53M | 20M |
| Q4 2023 | 159 | 99M | 82.5% | 28 / 43 | 58 / 37 | 18M | 15M |
| Q3 2023 | 170 | 95M | 79.7% | 20 / 59 | 56 / 36 | 10M | 22M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of FATE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,194,411 | 2.67% | $8.62M | 0.00% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 2,962,683 | 2.47% | $8.00M | 0.07% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,149,276 | 0.96% | $3.10M | 0.00% | Jun 30, 2026 |
| Bruce Fund | 989,188 | 0.83% | $2.67M | 0.71% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 876,106 | 0.73% | $2.49M | 0.05% | May 29, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 786,810 | 0.66% | $2.12M | 0.07% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 629,759 | 0.53% | $1.70M | 0.02% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 559,342 | 0.47% | $1.59M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 535,817 | 0.45% | $1.52M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 507,444 | 0.42% | $1.44M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 378,180 | 0.32% | $1.02M | 0.07% | Jun 30, 2026 |
| Vanguard Market Neutral Fund | 308,409 | 0.26% | $832.70K | 0.14% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 292,658 | 0.24% | $831.15K | 0.00% | May 31, 2026 |
| AQR Small Cap Multi-Style Fund | 256,360 | 0.21% | $692.17K | 0.18% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Growth Fund | 233,942 | 0.20% | $631.64K | 0.08% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Bahram Valamehr | President and CEO, Director | 591,815 | 0.49% | Aug 5, 2026 |
| Cindy Tahl | See Remarks | 589,355 | 0.49% | Aug 5, 2026 |
| Kamal Adawi | Chief Financial Officer | 100,000 | 0.08% | Jan 16, 2026 |
| Jerome Charles Bressi | See Remarks | 335,203 | 0.28% | Jan 16, 2025 |
| William H. Rastetter | Director | 642,424 | 0.54% | Jun 15, 2026 |
| Robert S. Epstein | Director | 36,331 | 0.03% | Jun 15, 2026 |
| Michael Stewart Lee | Director | 11,331 | 0.01% | Jun 15, 2026 |
| Karin Jooss | Director | 9,848 | 0.01% | Jun 15, 2026 |
| Shefali Agarwal | Director | 10,490 | 0.01% | Jun 15, 2026 |
| Yuan Xu | Director | 8,669 | 0.01% | Jun 15, 2026 |
| Redmile Group, LLC | Director, 10% owner | 13,135,758 | 10.96% | Jun 15, 2026 |
| Jeremy Green | Director, 10% owner | 12,884,277 | 10.75% | Jun 15, 2026 |
| Matt Abernethy | Director | – | – | Jun 15, 2026 |
| Laura Hamill | Director | – | – | Jun 15, 2026 |
| RedCo II Master Fund, L.P. | Director, 10% owner | 8,977,624 | 7.49% | Apr 23, 2026 |
| Neelufar Mozaffarian | Director | – | – | May 30, 2025 |
| John Mendlein | Director | 311,231 | 0.26% | May 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Cindy Tahl See Remarks | Aug 4, 2026 | Sale | −38,800 | $2.46 | $95.45K | 589,355 |
| Bahram Valamehr President and CEO, Director | Aug 4, 2026 | Sale | −43,947 | $2.46 | $108.11K | 591,815 |
| Bahram Valamehr President and CEO, Director | May 20, 2026 | Sale | −28,946 | $1.88 | $54.42K | 635,762 |
| Cindy Tahl See Remarks | May 20, 2026 | Sale | −25,590 | $1.88 | $48.11K | 628,155 |
| Cindy Tahl See Remarks | May 6, 2026 | Option exercise | +44,444 | $1.05 | $46.67K | 653,745 |
| Cindy Tahl See Remarks | May 6, 2026 | Option exercise | +122,220 | $1.32 | $161.33K | 609,301 |
| William H. Rastetter Director | May 5, 2026 | Option exercise | +25,000 | $1.69 | $42.25K | 36,331 |
| Robert S. Epstein Director | May 5, 2026 | Option exercise | +25,000 | $1.69 | $42.25K | 36,331 |
| Jeremy Green Director, 10% owner | Apr 20, 2026 | Other | −8,977,624 | – | – | 0 |
| Jeremy Green Director, 10% owner | Apr 20, 2026 | Other | +8,977,624 | – | – | 12,884,277 |
| Cindy Tahl See Remarks | Jan 15, 2026 | Award | +100,000 | – | – | 487,081 |
| Bahram Valamehr President and CEO, Director | Jan 15, 2026 | Award | +335,000 | – | – | 664,708 |
| Kamal Adawi Chief Financial Officer | Jan 15, 2026 | Award | +25,000 | – | – | 100,000 |
| Cindy Tahl See Remarks | Jan 9, 2026 | Sale | −10,589 | $1.06 | $11.22K | 387,081 |
| Bahram Valamehr President and CEO, Director | Jan 9, 2026 | Sale | −5,190 | $1.07 | $5.55K | 329,708 |
| Kamal Adawi Chief Financial Officer | Oct 20, 2025 | Award | +75,000 | – | – | 75,000 |
| Cindy Tahl See Remarks | Aug 4, 2025 | Sale | −9,037 | $1.06 | $9.58K | 397,670 |
| Bahram Valamehr President and CEO, Director | Aug 4, 2025 | Sale | −14,466 | $1.06 | $15.33K | 334,898 |
| Cindy Tahl See Remarks | Jan 15, 2025 | Award | +70,000 | – | – | 406,707 |
| Jerome Charles Bressi See Remarks | Jan 15, 2025 | Award | +65,000 | – | – | 335,203 |
| Cindy Tahl See Remarks | Jan 10, 2025 | Sale | −5,654 | $1.55 | $8.76K | 336,707 |
| Jerome Charles Bressi See Remarks | Jan 10, 2025 | Sale | −5,980 | $1.55 | $9.27K | 270,203 |
| Bahram Valamehr President and CEO, Director | Jan 10, 2025 | Sale | −8,705 | $1.54 | $13.41K | 349,364 |
| Jeremy Green Director, 10% owner | Dec 20, 2024 | Buy | +397,964 | $1.68 | $668.58K | 12,884,277 |
| Jeremy Green Director, 10% owner | Dec 20, 2024 | Other | −1,084,936 | $1.68 | $1.82M | 11,743,010 |
| Jeremy Green Director, 10% owner | Dec 20, 2024 | Other | +1,084,936 | $1.68 | $1.82M | 12,827,946 |
| Jeremy Green Director, 10% owner | Dec 20, 2024 | Sale | −341,633 | $1.68 | $573.94K | 12,486,313 |
| Jeremy Green Director, 10% owner | Dec 12, 2024 | Conversion | +30,110 | – | – | 12,827,946 |
| Yuan Xu Director | Aug 6, 2024 | Sale(10b5-1 plan) | −633 | $4.23 | $2.68K | 8,669 |
| Cindy Tahl General Counsel and Secretary | Jul 29, 2024 | Award | +200,000 | – | – | 342,361 |
| Bahram Valamehr Chief R&D Officer | Jul 29, 2024 | Award | +200,000 | – | – | 358,069 |
| Edward J. Dulac III Chief Financial Officer | Mar 4, 2024 | Sale(10b5-1 plan) | −2,447 | $7.77 | $19.01K | 101,479 |
| Edward J. Dulac III Chief Financial Officer | Jan 29, 2024 | Sale(10b5-1 plan) | −1,849 | $5.00 | $9.25K | 103,926 |
| Cindy Tahl General Counsel and Secretary | Jan 9, 2024 | Sale | −10,874 | $4.37 | $47.52K | 142,361 |
| Bahram Valamehr Chief R&D Officer | Jan 9, 2024 | Sale | −11,271 | $4.38 | $49.37K | 158,069 |
| Edward J. Dulac III Chief Financial Officer | Jan 9, 2024 | Sale | −7,028 | $4.37 | $30.71K | 105,775 |
| J. Scott Wolchko President and CEO, Director | Jan 9, 2024 | Sale | −14,391 | $4.37 | $62.89K | 371,248 |
| Edward J. Dulac III Chief Financial Officer | Jan 2, 2024 | Sale(10b5-1 plan) | −5,182 | $3.66 | $18.97K | 112,803 |
| Redmile Group, LLC Director, 10% owner | Dec 26, 2023 | Other | −1,655,370 | $3.72 | $6.16M | 13,135,758 |
| Redmile Group, LLC Director, 10% owner | Dec 26, 2023 | Other | +1,655,370 | $3.72 | $6.16M | 13,135,758 |
| Redmile Group, LLC Director, 10% owner | Dec 26, 2023 | Buy | +44,630 | $3.72 | $166.02K | 13,180,388 |
| Edward J. Dulac III Chief Financial Officer | Dec 18, 2023 | Sale(10b5-1 plan) | −1,585 | $3.50 | $5.55K | 117,985 |
| Cindy Tahl General Counsel and Secretary | Nov 9, 2023 | Sale(10b5-1 plan) | −24,363 | $2.40 | $58.47K | 153,235 |
| Edward J. Dulac III Chief Financial Officer | Aug 18, 2023 | Sale | −4,718 | $2.80 | $13.21K | 119,570 |
| Yuan Xu Director | Aug 4, 2023 | Sale(10b5-1 plan) | −632 | $3.71 | $2.34K | 9,302 |
| Brian T. Powl Chief Commercial Officer | Jul 5, 2023 | Sale | −3,854 | $4.87 | $18.77K | 41,146 |
| Edward J. Dulac III Chief Financial Officer | Jul 5, 2023 | Sale(10b5-1 plan) | −5,182 | $4.83 | $25.03K | 124,288 |
| Yuan Xu Director | Jun 14, 2023 | Sale(10b5-1 plan) | −3,460 | $5.58 | $19.31K | 9,934 |
| Jeremy Green Director, 10% owner | Apr 21, 2023 | Buy | +256,639 | $6.18 | $1.59M | 13,135,758 |
| Jeremy Green Director, 10% owner | Apr 20, 2023 | Buy | +20,000 | $5.99 | $119.80K | 12,879,119 |
| Yu-Waye Chu Chief Medical Officer | Apr 18, 2023 | Sale(10b5-1 plan) | −2,317 | $6.58 | $15.25K | 140,676 |
| Yu-Waye Chu Chief Medical Officer | Apr 18, 2023 | Sale(10b5-1 plan) | −215 | $6.52 | $1.40K | 142,993 |
| Jeremy Green Director, 10% owner | Apr 14, 2023 | Sale | −302,339 | $5.84 | $1.77M | 12,833,419 |
| Jeremy Green Director, 10% owner | Apr 14, 2023 | Other | −5,492,385 | $5.84 | $32.08M | 12,833,419 |
| Jeremy Green Director, 10% owner | Apr 14, 2023 | Buy | +25,700 | $6.00 | $154.20K | 12,859,119 |
| Jeremy Green Director, 10% owner | Apr 14, 2023 | Other | +5,492,385 | $5.84 | $32.08M | 12,833,419 |
| Jeremy Green Director, 10% owner | Apr 13, 2023 | Conversion | +167,205 | – | – | 13,135,758 |
| John Mendlein Director | Jan 19, 2023 | Option exercise | +28,461 | $1.37 | $38.99K | 311,231 |
| John Mendlein Director | Jan 13, 2023 | Buy | +36,631 | $5.43 | $198.91K | 282,770 |
| Bahram Valamehr Chief R&D Officer | Jan 12, 2023 | Option exercise | +423 | $1.37 | $580 | 169,340 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Cindy Tahl Officer | Aug 4, 2026 | 38,800 | $95.41K | Aug 4, 2026 | Restricted Stock Vesting |
| Bahram Valamehr Officer, Director | Aug 4, 2026 | 43,947 | $108.10K | Aug 4, 2026 | Restricted Stock Vesting |
| Cindy Tahl Officer | May 20, 2026 | 25,590 | $48.08K | May 20, 2026 | Restricted Stock Vesting |
| Bahram Valamehr Officer, Director | May 20, 2026 | 28,946 | $54.48K | May 20, 2026 | Restricted Stock Vesting |
| Cindy Tahl Officer | Jan 9, 2026 | 10,589 | $11.28K | Jan 9, 2026 | Restricted Stock Vesting |
| Bahram Valamehr Officer, Director | Jan 9, 2026 | 5,190 | $5.56K | Jan 9, 2026 | Restricted Stock Vesting |
| John Mendlein Former Director | Dec 29, 2025 | 38,428 | $38.88K | Dec 24, 2025 | Restricted Stock Vesting |
| Cindy Tahl Officer | Aug 4, 2025 | 9,037 | $9.57K | Aug 4, 2025 | Restricted Stock Vesting |
| Bahram Valamehr Officer, Director | Aug 4, 2025 | 14,466 | $15.40K | Aug 4, 2025 | Restricted Stock Vesting |
| J. Scott Wolchko Former Officer and Director | Mar 6, 2025 | 113,178 | $104.88K | Mar 6, 2025 | Restricted Stock Vesting |
| Bahram Valamehr Officer, Director | Jan 10, 2025 | 8,705 | $13.45K | Jan 10, 2025 | Restricted Stock Vesting |
| Cindy Tahl Officer | Jan 10, 2025 | 5,654 | $8.78K | Jan 10, 2025 | Restricted Stock Vesting |
| Jerome Charles Bressi Officer | Jan 10, 2025 | 5,980 | $9.28K | Jan 10, 2025 | Restricted Stock Vesting |
| Redmile Group, LLC Director, 10% Stockholder | Dec 20, 2024 | 341,633 | $567.11K | Dec 20, 2024 | Private Placements from Stockholders |
| Yuan Xu Director | Aug 6, 2024 | 633 | $2.68K | Aug 6, 2024 | Restricted Stock Vesting |